<DOC>
	<DOCNO>NCT00677859</DOCNO>
	<brief_summary>The purpose study determine MultiStem® safely give patient acute leukemia , chronic myeloid leukemia , myelodysplasia receive hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Safety Study MultiStem® Patients With Acute Leukemia , Chronic Myeloid Leukemia , Myelodysplasia</brief_title>
	<detailed_description>Graft-vs.-Host Disease ( GVHD ) one major limitation allogeneic hematopoietic stem cell transplant ( HSCT ) . This complication major cause morbidity mortality think initiate activation donor T-cells recognition `` foreign '' cell resident transplant recipient . Acute GVHD associate damage liver , skin , gastrointestinal tract mucosa . Moderate severe GVHD Grades II-IV occur 30-50 % match related HSCTs 50-70 % unrelated donor recipient . Severe GHVD require intense immunosuppression involve steroid additional agent get control , patient may develop severe infection result immunosuppression . An agent cell therapy could reduce incidence and/or severity GVHD without increase relapse infectious risk HSCT patient would provide substantial benefit .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>Patients either sex aged 1865 year age Diagnosis acute myeloid lymphoblastic leukemia ( second subsequent remission , remission , &lt; 20 % bone marrow blast ) , chronic myelogenous leukemia resistant intolerant tyrosine kinase inhibitor therapy ( accelerated phase , first chronic phase TKI resistance , second chronic phase ) , myelodysplastic syndrome ( intermediate/high high risk International Prognostic Scoring System ( IPSS ) , low risk IPSS patient progress prior therapy . Complete remission define absence blast peripheral circulation time enrollment &lt; 5 % blast marrow within 28 day enrollment . Life expectancy least 100 day Patients scheduled allogeneic bone marrow transplant peripheral blood stem cell transplant ( PBST ) procedure Familyrelated unrelated donor HLA match either match relate matched unrelated donor , 6/6 match 5/6 single allelic mismatch , provision DRB1 molecularly match Performance status ( ECOG ≤2 ) Signed informed consent Active infection Known allergy bovine porcine product Renal function : Serum creatinine &gt; 2 mg/dL creatinine clearance ≤50 mL/min Hepatic function : Screening ALT AST ≥3x upper limit normal laboratory OR total bilirubin ≥2.0 mg/dL ( Exception : acceptable patient identify preexist condition e.g. , Gilbert 's disease contribute baseline elevation bilirubin ) Pulmonary function : FEV1 , FVC , DLCO ≤50 % predict Cardiac function : leave ventricular ejection fraction ≤50 % Patient receive investigational agent within 30 day prior transplant The patient pregnant , positive serum BhCG , lactate Patient corticosteroid dose &gt; 0.25 mg/kg/day Planned nonmyeloablative transplant Planned cord blood transplant Prior allogeneic myeloablative HSCT HIV seropositive , HTLV seropositive , hepatitis B C seropositive , varicella virus active infection , syphilis active infection Other serious medical psychiatric illness , investigator 's opinion , would permit patient manage accord protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Graft v . Host Disease</keyword>
	<keyword>Hematopoietic Stem Cell Transplant</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Myelodysplasia</keyword>
</DOC>